DRTS Profile
Alpha Tau Medical Ltd., headquartered in Jerusalem, Israel, operates as a clinical-stage oncology therapeutics company specializing in the research, development, and commercialization of innovative cancer treatments. Central to its portfolio is the pioneering diffusing alpha-emitters radiation therapy (Alpha DaRT), designed to effectively target and treat solid tumors. This groundbreaking technology is currently undergoing clinical trials for a spectrum of cancers including skin, oral, pancreatic, and breast cancers, showcasing its potential across diverse oncological applications.
Founded in 2015, Alpha Tau Medical Ltd. has rapidly advanced its Alpha-DaRT platform, demonstrating promising results in preclinical studies focused on challenging cancers such as hepatic cell carcinoma, glioblastoma multiforme, and lung cancer.r. The company's commitment to rigorous scientific research and development underscores its mission to redefine cancer treatment paradigms, offering patients new hope through innovative therapeutic approaches.
Through strategic collaborations with leading medical institutions and oncology centers, Alpha Tau Medical Ltd. continues to expand its clinical footprint in Israel and the United States, positioning itself as a frontrunner in the field of targeted radiation therapies. By leveraging cutting-edge technology and clinical expertise, the company aims to advance regulatory approvals and commercialize Alpha DaRT on a global scale, addressing unmet medical needs and improving patient outcomes worldwide.
With a dedicated team of researchers, clinicians, and industry experts, Alpha Tau Medical Ltd. remains steadfast in its pursuit of transforming cancer care through precision medicine and advanced radiation therapies. As it progresses towards commercialization, the company remains committed to fostering innovation, enhancing treatment efficacy, and ultimately, contributing to the fight against cancer with compassion and scientific excellence.
|
